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Introduction
Identification of differentially expressed
pathways from expression data is an
important problem because it allows us to
gain insights into the functional working
mechanism of cells beyond the detection of
differentially expressed genes. In this paper
we present a brief guide to methods for the
pathway analysis of expression data. De-
spite the vast amount of different statistical
methods that have been developed so far,
there is a considerable similarity among
them, allowing a systematic classification
and a reduction to a few null hypotheses
that are effectively tested.
Systems biology aims to find emergent
phenomena by the integration of heteroge-
neous data. In general, data integration
itself is a part of any scientific inference: its
elementary steps are the integration of
observations (measurements) into the con-
text of biological knowledge. However, in
the case of systems biology, the scale of
integration is many folds higher, resulting
in a prodigious number of new computa-
tional approaches for the simultaneous
analyses of heterogeneous data. In this
paper we discuss one popular way of
integrating biological knowledge into
large-scale genome-wide measurements,
namely the identification of functionally
related genes (pathways) enriched or differ-
entially expressed in gene expression data
[1]. It should be noted that the approaches
discussed are also applicable to the analyses
of, e.g., RNA-seq, metabolomics or pro-
teomics data and, generally, different types
of biological measurements when preexist-
ing biological knowledge is available.
In the early stages of methodological
developments for gene expression data
analyses, most approaches were focused
on producing so-called gene lists. This is a
set of individual genes called differentially
expressed as identified by univariate test
statistics (e.g., a t-test) [2–4]. Instead, more
recent approaches clearly reflect systems
biology’s trend of data integration and
interpretation [5–7], focusing on sets of
functionally related genes (e.g., from the
same signaling or metabolic pathway)
rather than individual genes.
The purpose of this paper is to provide
a brief guide to methods for the analysis of
differentially expressed pathways or gene
sets, which we simply call pathway-based
methods. For this reason, we emphasize an
illustration of the methods rather than
their technical description. The reader is




In order to gain a deeper appreciation
for the underlying concepts of methods
aiming to identify differentially expressed
pathways, we briefly describe their overall
goal and some basic facts of molecular
systems. First of all, the ultimate goal of
pathway-based approaches is to connect a
molecular level with a phenotype of an
organism causally or at least associatively.
In the case of a disease-related phenotype,
this could mean that certain molecular
processes are responsible for the manifes-
tation or development of a disease [8,9].
The difficulty in achieving this goal is not
only technical, e.g., deciding which method
would allow us to decipher molecular
mechanisms underlying disease pheno-
types. The selection of appropriate entities
at the molecular level, serving as measure-
ment variables to capture relevant infor-
mation, remains an open problem as well.
Despite considerable differences between
many pathway-based approaches [5], their
common theme is to focus on a systems
level of functional components [10–12] of
the molecular system comprising many, as
opposed to individual, genes.
The analysis of pathways that are signif-
icantly differentially expressed is intuitively
appealing and there are several reasons in
support of this. First, by arranging genes into
pathways, the dimensionality of the dataset is
reduced, and as a consequence the number
of statistical hypotheses that need to be
tested. Second, the statement ‘‘a gene is
differentially expressed between two pheno-
t y p e s ’ ’h a s ,f r o mab i o l o g i c a lp o i n to fv i e w ,
less explanatory power compared to the
statement ‘‘a pathway is differentially ex-
pressed between two phenotypes’’, because
genes do not function in isolation but are
interconnected with each other, forming
gene networks, e.g., a transcriptional regula-
tory, metabolic, or protein network [11,13].
Third, frequently, genes in a list of differen-
tially expressed genes are highly correlated,
which increases the probability of a large
number of false positives. Considering
pathways or gene sets instead of individual
genes leverages the correlation problem to
some extent, because genes in a gene set
frequently act in a coordinated manner
together, forming a biological process, e.g.,
DNA repair or protein catabolic process.
Recently, an alternative approach to handle
the correlation among genes has been
suggested by Zuber and Strimmer [14] by
calculating correlation-adjusted t-scores (the
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ences between two samples). However, the
idea of looking for differentially expressed
pathways appeared with a different reason-
ing in mind. Generally, it is believed that in
many diseases the changes in the expression
values of genes are only moderate and
undetectable for individual genes. For
example, while there were no differentially
expressed individualgenes between Type II
diabetespositiveandnegativepatients,a set
of genes involved in oxidative phosphory-
lation was coordinately decreased in hu-
man diabetic muscle [7]. Following this
work, Subramanian et al. [15] described
one of the first algorithms (Gene Set
Enrichment Analysis, GSEA) focusing on
the expression changes of a set of genes as
opposed to changes in the expression of
individual genes.
General Aspects
Before we present pathway-based ap-
proaches, we want to note that there are
two general aspects that need to be
addressed properly in order to ensure a
sound analysis. The first is the preprocess-
ing of the data and the second is the
correction for multiple hypothesis testing.
Here, it is important to realize that the
preprocessing of the data and their
subsequent analysis are not independent
from each other, but the preprocessing
and the analysis of the data need to ‘‘fit
together’’. Despite the fact that these two
topics do not form the major focus of this
paper, we present a brief discussion to
assist the reader in understanding their
importance.
The preprocessing of the gene expres-
sion data obtained using microarrays
addresses three issues. (1) Background
correction: adjusting for hybridization
effects, (2) normalization: removing sys-
tematic errors and biases to allow com-
parisons among arrays, and (3) summari-
zation: combining multiple probe
intensities to obtain a single value for each
gene. There is a rich literature devoted to
this important topic that provides guid-
ance in the selection of appropriate
preprocessing procedures [16–18]. A gen-
tle introduction can be found in [19]. For
more discussions about various aspects of
this difficult topic, the reader is referred to
[20–22]. The second problem that needs
to be addressed is the correction for
multiple hypothesis testing [23–26]. There
are various error measures that have been
used to control a Type I error rate.
Principally, one can distinguish them with
respect to the information that they are
using. For example, there are Type I error
rates based on false positives (N1j0)o ro n
the false discovery proportion (FDP). Here,
the false discovery proportion is FDP~
N1j0=R for R.0 and zero for R=0, with R
being the number of significant tests. In the
context of microarray data for identifying
differentially expressed genes, there have
been extensive studies conducted providing
guidance in selecting an appropriate mul-
tiple testing procedure [3,27,28]. However,
for pathway-based approaches, this prob-
lem has received considerably less attention
and is currently still under investigation.
For this reason, it is advisable to investigate
carefully what error rate and procedure is
most appropriate for given circumstances.
Pathway-Based Approaches
In the following, we provide an overview
of different pathway-based methods.
Figure 1 illustrates a general taxonomy of
various pathway analysis strategies. Over-
all, there are three major decisions to make
(indicated by the numbers in the red boxes
inFigure1):The firstdecision(Figure1,red
box 1) defines whether pre-selected gene
lists are used in the analysis. The second
decision (Figure 1, red box 2) determines
the type of the null hypothesis (H0) that will
be tested in the analysis. The third decision
(Figure 1, red box 3) connects particular
null hypotheses and statistical tests.
It appears natural that the earliest
pathway-based approaches resulted from
the analysis of the differential expression of
individual genes (Figure 1, left column
‘‘over-representation analysis’’, also called
‘‘gene lists’’). The analysis of the differen-
tial expression of individual genes results
in a gene list, i.e., a data sheet of genes
called differentially expressed (DE) as
declared by an univariate test (see
Figure 1, ‘‘How to: create a pre-selected
gene list’’). We want to emphasize that this
gene list is called a pre-selected gene list in the
literature [29]. This is an unfortunate
convention because it is easy to confuse
this gene list with a gene set as defined by,
e.g., the Gene Ontology (GO) database
(see below). Then, instead of considering
genes one by one, one can ask ‘‘Do all
these genes, declared differentially ex-
pressed, have any biological function in
common?’’ To answer this question one
should know the gene sets with common
biological functions. These gene sets can
be defined either ad hoc as genes that are
‘‘interesting’’, e.g., the set of prostate
cancer-related genes, or, as is more
common in this type of analysis, using
functional categories, e.g., from the GO
database [30]. The next step is to decide
whether a set of interest, e.g., from GO, is
overrepresented in the DE set. Here,
overrepresented could mean that genes
involved in apoptosis appear more fre-
quently than expected by chance in the list
of DE genes. Many conventional statistical
tests can be applied for answering this
question, e.g., Fisher’s exact test (see
Figure 1, Table 1, and [29,31] for a
review). However, despite its popularity
and simplicity, this approach has several
shortcomings. For instance, the power of
this approach is entirely defined by the list
of pre-selected genes. The content and the
size of a gene list, in turn, is defined by the
types of the univariate test statistic and
multiple testing procedure chosen for
selecting individual genes; see Allison
et al. [32] for more discussions about the
analysis of individual differentially ex-
pressed genes. Most importantly, over-
representation analysis ignores all genes
that were not included in the list of pre-
selected genes, increasing the chances for
missing a biological signal [29,33]. The
approaches without pre-selected gene lists
(Figure 1, right column ‘‘Approaches
without pre-selected gene lists’’, and
Table 1) do not have these limitations.
For this reason we focus in the remainder
of this paper on the latter approach.
Principle Differences: Null
Hypothesis
One in the meanwhile classic approach
that does not rely on pre-selected gene lists
is GSEA [7,15]. The simplified working
mechanism of the GSEA method can be
summarized as follows: (1) Rank all genes
in a dataset according to their expression
differences between two phenotypes. (2)
For each gene set (groups of functionally
linked genes from, e.g., GO) calculate an
enrichment score (ES), where ES is a
running sum statistic reflecting the spread
of the members of a gene set among all
ranked genes. From this select the maxi-
mum enrichment score (MES). (3) Calcu-
late the significance of the MES from the
null distribution of MESs for phenotype-
label randomized data.
Since the appearance of GSEA, many
approaches have been suggested for the
analysis of gene sets [34–37] and their
number is still growing; see Ackermann
and Strimmer [34] for a review. All these
approaches aim to identify gene sets that
change their expression significantly be-
tween phenotypes, where genes in a set
may belong to the same biological process.
The definition of gene sets can be obtained
from databases like the Kyoto Encyclope-
dia of Genes and Genomes [38], Gene
Ontology [30], GenMAPP [39], or Re-
PLoS Computational Biology | www.ploscompbiol.org 2 May 2011 | Volume 7 | Issue 5 | e1002053Figure 1. An overview of motivations and strategies, underlying statistical hypotheses and corresponding tests for pathway-
analysis.
doi:10.1371/journal.pcbi.1002053.g001
Table 1. Overview of different pathway-based methods.
Principle Method Reference Type Software
Over-representation analysis Huang et al. [29] Competitive GOstats and http://www.geneontology.org/GO.tools.
microarray.shtml
Gene set enrichment analysis Mootha et al. [7] Competitive GSEABase and http://www.broad.mit.edu/gsea/
Subramanian et al. [15] Competitive GSEABase and http://www.broad.mit.edu/gsea/
Efron et al. [58] Competitive No
GAGE: GSEA extension Luo et al. [59] Competetive GAGE
PAGE Kim et al. [35] Competitive PGSEA, GAGE
Random Sets Newton et al. [60] Competetive Part of CLEAN
Generalized Random Sets Freudenberg et al. [61] Competetive http://GenomicsPortals.org/
Average of single-gene statistics Tian et al. [48] Self-contained sigPathway
Linear Model Toolset for GSEA Jiang et al. [49] Self-contained GSEAlm
SAM-GS Dinu et al. [62] Self-contained http://www.ualberta.ca/,yyasui/SAM-GS/
globaltest Goeman et al. [63] Self-contained globaltest
GlobalANCOVA Hummel et al. [46] Self-contained GlobalAncova
Hotelling’s T
2 [43–45] Self-contained PCOT2
N-statistic Klebanov et al. [47] Self-contained Cramer, R package
Where available, a link to the software or the name of the Bioconductor package (http://www.bioconductor.org/help/bioc-views/release/bioc/) [57] is provided.
doi:10.1371/journal.pcbi.1002053.t001
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argued [6] that the major difference
between these approaches can be formu-
lated in terms of competitive and self-contained
tests. Competitive tests compare the dif-
ferential expression of a gene set against
the remainder of all genes, and self-
contained tests answer the question wheth-
er a gene set is differentially expressed
between different phenotypes. Subse-
quently, different null hypothesis Q1 and
Q2 are tested [6] (Figure 1, right column,
Q1 and Q2; and Table 1).
(Q1) Null hypothesis of competitive
approaches:
The genes in a set are as often differen-
tially expressed as the genes in the rest of
the sets.
(Q2) Null hypothesis of self-contained
approaches:
No genes in a set are differentially
expressed.
Dinu and colleagues [41] have demon-
strated that the power of competitive and
self-contained tests cannot be compared
objectively in simulation studies because
the decision as to which test has more
power depends crucially on the hypotheses
(Q1 or Q2) underlying the simulation of
the data, favoring the data-generating
hypothesis. On the other hand, several
arguments have been raised in favor of
self-contained tests [6]:
1. They represent an immediate general-
ization of single-gene tests.
2. Their null hypothesis has a clear
biological interpretation.
3. They make sense even if we consider
all genes on a chip simultaneously,
whereas a competitive test does not.
In summary, this means self-contained
tests are easy to interpret biologically and
they can be more powerful compared to
competitive tests. Table 1 provides an
overview of various competitive and self-
contained tests, including information
about the availability of software imple-
mentations. In the following we discuss
self-contained tests only, and the interested
reader is referred to [42] for a comparative
power analysis of competitive tests.
Differences among Self-
Contained Tests
Self-contained tests can be distinguished
in terms of whether they are multivariate
and account for interdependencies among
genes (e.g., Hotelling’s T
2 test: [43–45];
GlobalANCOVA: [46]; N-statistic: [47];
Table 1) or disregard existing complex
correlation structures in a gene set and
consider gene-level statistics only (e.g.,
weighted sum of t-tests: [48]; median-
based or sign-tests: [49]; Table 1). Further,
for gene-level statistics, a transformation of
the test statistic is frequently applied in
order to account for the presence of up-
and down-regulated genes in a gene set
[34]. However, more importantly, for
univariate and multivariate self-contained
tests, the underlying statistical hypotheses
are different. For example: Hotelling’s T
2
tests the equality of two multivariate mean
vectors, while the N-statistic tests the
equality of two multivariate distributions.
A combination of univariate statistics
(either transformed or not) assesses wheth-
er the aggregate gene-level test score
differentiates between two phenotypes
[49]. We want to emphasize that due to
these complementing null hypotheses,
each test projects on different aspects of
the data. There are many more self-
contained tests available [34]; however,
effectively, there appear to be barely more
than three general types of underlying null
hypotheses being tested [1].
In order to choose the most appropriate
test, one needs to know their relative
power in different settings and the differ-
ent null hypotheses they test. For this
reason, we presented in [1] a comparative
power analysis for univariate and multi-
variate self-contained tests on simulated
and biological data focusing on three
major issues. First, not all genes in a gene
set change their expression between dif-
ferent phenotypes. The percent of genes
that are actually changing their expression
in a gene set, referred to as detection call,
in the way that the entire gene set is called
differentially expressed, is an important,
but currently unknown, characteristic of
the performance of a test. Second, genes in
a gene set that are functionally related to
each other might exhibit a complex
correlation structure [50]. Multivariate
tests might have a higher power because
they account for interdependences among
genes considering the joint distribution of
gene expression levels, in contrast to
univariate tests, which test differences in
the marginal distributions. The third
question is an implication of the second:
one might expect that because univariate
and multivariate statistics test different null
hypotheses, for real biological data they
may result in completely different gene
sets. There is a reason for concern here:
for example, the application of Principal
Component Analysis and gene-level tests
resulted in exactly this scenario [49]. In [1]
we answered the first two questions with
simulated data, mimicking the stated
conditions, and the third one with two
biological data sets from acute lympho-
blastic leukemia and NCI-60 cell lines. As
a result, we found that all tests perform
reasonably well in estimating the Type I
error rate. Among the three parameters
varied in the simulations (the magnitude of
pairwise correlations among gene expres-
sions, the number of genes changing their
expression in a set, and the size of a gene
set), the magnitude of pairwise correlations
has the largest influence on the power of
all tests. Despite the general belief that
multivariate tests account for a complex
interdependence structure between genes
and, hence, may result in a better power
compared to univariate tests, our study
demonstrated that this is not true when
high correlations are present. Further, we
found that the performance of all tests
coincides when the following three condi-
tions hold:
1. The correlation among genes is low.
2. The number of genes in a pathway is
relatively large.
3. The percent of genes changing signif-
icantly their expression (detection call)
is high.
Due to the fact that for biological data
these three conditions may hold only with
varying degree, differences in these tests
are expected. From the two univariate and
three multivariate self-contained tests used
in our previous study, only three of them
can be considered conceptually different
with respect to their underlying null
hypotheses. It appears that these three
null hypotheses cover the vast majority of
the current universe of all self-contained
tests employed until now. Due to their
complementing null hypotheses, each test
projects on different aspects of the data.
This suggests the simultaneous usage of
several tests in order to gain power
compared to each of these tests individu-
ally. For technical details about pathway
approaches, the reader is referred to the
following recent review papers [34,41,51].
Discussion and Conclusions
The analysis of pathways or gene sets
differentially expressed between pheno-
types has became a routine approach for
the analysis of gene expression data.
Despite the wealth of different methods
available for such an analysis, there exist
considerable similarities among them,
allowing for a systematic classification
and a reduction to a few null hypotheses
that can be tested effectively [1,34].
Figure 1 illustrates that at present there
appear only to be five different null
PLoS Computational Biology | www.ploscompbiol.org 4 May 2011 | Volume 7 | Issue 5 | e1002053hypotheses behind all pathway analysis
strategies. An important take-home mes-
sage from this is that testing all these null
hypotheses would be the most compre-
hensive way to highlight different aspects
of the data and increase the chances of
retrieving a meaningful biological signal.
In addition, it would allow one to distill a
strong biological signal, if present, in the
intersection of the results. We expect that
further developments in this field will
allow for the consideration of the hetero-
geneity of gene expression in a gene set
and also allow for the integration of
additional biological information, e.g.,
the topology of a pathway [52] in the
analysis. Another problem that deserves
more attention is the overlapping among
gene sets that leads to complications in the
interpretation of obtained results. An
enrichment map has been suggested as a
visual interpretation guide [53], but fur-
ther investigations are necessary to address
the hierarchical organization among these
gene sets; see also [54,55] for further
attempts in this direction. Finally, we
would like to emphasize that despite the
fact that in this paper we focused entirely
on expression data from microarray ex-
periments, many of the discussed methods
translate to data from other technology
platforms, e.g., RNA-seq [56].
We conclude with a general note of
caution. Although many of the presented
methods are available as easily usable
software packages, we do not want to give
the impression that these methods should
be used in a plug-and-play manner. Quite
the contrary. Each of these methods and
the resulting findings need to be selected,
applied, and interpreted mindfully, paying
close attention to relevant statistical and
domain-specific details in order to impede
fallacious conclusions.
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